Market Research Logo

Global Non-Invasive Prenatal Testing and Newborn Screening Market, 2017-2027

Global Non-Invasive Prenatal Testing and Newborn Screening Market, 2017-2027

It has been estimated that close to 131 million babies are born each year across the globe. Of these, approximately 7.9 million are born with birth defects. In fact, more than 7,000 genetic disorders have been identified so far and the number is rising. Genetic testing solutions that enable early detection of genetic abnormalities in fetuses and newborns are important to ensure that the person does not face complications later in life. With the emergence of innovative diagnostic and screening techniques, several methods of genetic testing have become popular. These include carrier testing, preimplantation genetic diagnosis / screening (PGD / PGS), prenatal testing, paternity testing and newborn screening. Amongst these, prenatal testing (primarily Non-invasive prenatal testing (NIPT)) and newborn screening have gained relatively more traction in prenatal and neonatal care.

Specifically, NIPT has emerged as an efficient screening method in prenatal care that can analyze the cell-free DNA (cfDNA) extracted from maternal blood sample during pregnancy. NIPTs offer several advantages over conventional prenatal testing procedures; in addition to being non-invasive, these tests offer shorter turnaround times and high accuracy. It has been reported that the increasing popularity of NIPTs has led to a 50% decline in the use of invasive prenatal testing procedures (such as amniocentesis and chorionic villus sampling (CVS)). With the changing mindset of people belonging to different cultural and socio-economic background, the uptake of NIPTs is likely to increase further. Moreover, with the rising awareness and availability of NIPTs designed for a wide array of disease indications, and development of innovative and versatile technologies, we expect that the interest will continue to grow.
Within neonatal care, the emergence of advanced technologies in this domain has reflected a gradual rise in the overall development of advanced newborn screening tests in the last few years. In fact, public service bodies in more than 70 countries across the globe have facilitated the establishment of newborn screening programs in their respective countries. With an already established platform, we expect the overall newborn screening market to continue its gradual rise driven by higher adoption, competitive prices and availability of these tests in various geographies across the globe.

SCOPE OF THE REPORT
The “Global Non-Invasive Prenatal Testing and Newborn Screening Market, 2017-2027” report features an extensive study on the current market landscape of non-invasive prenatal testing (NIPT) and newborn screening diagnostics that are commercially available or are under development. NIPT and newborn screening tests are designed for the detection of different types of genetic abnormalities in fetuses and newborns. Detection of genetic disorders in prenatal and neonatal stages is critical to lower the child mortality rates. Moreover, early detection, treatment and management of these genetic disorders is important to avoid serious health problems at later stages in life. The study offers a comprehensive discussion on the future potential of these tests in prenatal and neonatal care.

Ever since the launch and subsequent success of the first NIPT, the NIFTY® test (launched by BGI in August 2011), several firms have taken initiatives to develop and commercialize NIPTs. Currently, a number of NIPTs that are designed to screen for conditions such as chromosomal abnormalities, sex chromosomal abnormalities and microdeletion syndromes are available in the market. In addition, many companies have entered into collaborations to distribute these tests across various geographies in order to expand the availability to a wider population. Examples of popular NIPT tests include Harmony® test (Ariosa Diagnostics, acquired by Roche), PraenaTest® / PrenaTest® (LifeCodexx, a subsidiary of GATC Biotech), Panorama® (Natera®), NIFTY® (BGI), Verifi® (Verinata Health, acquired by Illumina®), VisibiliTTM (SequenomTM, acquired by LabCorp®) and IONA® test / Safe NIPT (Premaitha Health).

The advent of routine newborn screening in the 1960s for the detection of phenylketonuria (PKU) established the role and importance of newborn screening in mitigating disorders in newborns. The field is continuously evolving as the awareness related to benefits of newborn screening increases. Moreover, introduction of advanced technologies such as next-generation sequencing (NGS) and tandem mass spectroscopy has notably accelerated the development in this domain. Newborn screening diagnostics are primarily available for conditions such as metabolic disorders, endocrine disorders, hemoglobin disorders, congenital heart disorders and hearing disorders.

Both prenatal testing and newborn screening offer several benefits in terms of disease management in neonatal care and has gathered interest from a wide range of companies worldwide. In total, we have identified 76 NIPT tests and 38 advanced newborn screening tests. In addition, there are several companies that are engaged in the development of basic tests, devices, systems and technology platforms for both prenatal testing and newborn screening. One of the key objectives of this report was to understand the current activity and the future potential of the NIPT and newborn screening markets. Amongst other elements, the report covers the following:
NIPT:
 The overall landscape of NIPT tests with respect to the stage of development, sample type, technology platforms, type of indications, stage of pregnancy and result turnaround time. In addition, the report provides a detailed discussion and analysis on the various innovative technology platforms available for the development of NIPTs and the indications screened.
 Comprehensive profiles of the leading players in the field of NIPT and their products, highlighting details of the company, financial and funding information (if available), product portfolio and a comprehensive future outlook. Likewise, the product profiles provide information on the product and their development history, technology platforms, test procedure, specifications, advantages and clinical information (if available).
 An elaborate geographical coverage analysis of the NIPT tests available / under development across the globe, a comparative heat map analysis of NIPTs (on the basis of sensitivity, specificity, result turnaround time and stage of pregnancy when the test can be performed), harvey ball analysis highlighting the panel strength of each test based on the number of indications being screened, and the geographical distribution of the companies involved in the development of NIPTs.

Newborn Screening:
 The overall landscape of newborn screening tests with respect to the stage of development, screening type, technology platform, type of indication, period of sample collection after birth and result turnaround time.
 Detailed profiles of the players involved in the field of newborn screening and their products highlighting details on the company, financial and funding information (if available), product portfolio and a comprehensive future outlook. Likewise, the product profiles provide information on the product specifications and test methodology. In addition, the report includes a comprehensive list of the core and secondary disorders / deficiencies recommended for newborn screening.
 An illustrative grid representation of the newborn screening tests based on screening type (basic newborn screening, expanded newborn screening, comprehensive newborn screening and advanced newborn screening) and technology platform, and an overview of the landscape of industry developers (start-ups, mid-sized and large-sized players).

Additionally, the report includes:
 A detailed discussion of the existing regulatory landscape in the field of NIPT and the current status of the government mandated newborn screening programs established in various countries across the globe to provide proper medical care to newborns.
 Partnerships that have been recently been inked amongst different stakeholders, covering product distribution / marketing agreements, development / commercialization agreements and mergers / acquisitions.
 A detailed survey analysis primarily focused on gaining additional insights on the company’s tests or services, highlighting the focus area of the company, type of the products, purpose and commercial availability of the lead product(s).

The study features a detailed analysis on the existing size and future growth opportunities (2017-2027) in the NIPT and newborn screening markets. We have provided insights on the likely regional evolution of the NIPT market across patients in three risk group segments (high risk, average risk and low risk) covering North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe) Asia (Japan, China and India) and rest of the world. In addition, we have provided the likely distribution by type of indications, stage of pregnancy when the test can be conducted and the share of individual NIPTs. The forecast takes into account the impending price variations that are likely to emerge in the mid-long term as a result of growing adoption and increased competition. In order to account for uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market’s evolution.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data and primary research discussions. For the purpose of the study, we invited over 150 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These include contributions from Jim Patterson (Vice President, Sales and Marketing North America, EvolveGene®), Osama Fikry (Metabolic and Diagnostic Head, NewBridge Pharmaceuticals) and Silke Arndt (Medical Scientist and NGS Manager, Inqaba Biotec). All financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. During our research, we identified 76 NIPTs; of the commercially available tests, majority are laboratory-developed tests while only a few are CE-IVD certified. The CE-IVD marked tests include Clarigo® (Multiplicom), Harmony® test (Ariosa Diagnostics, acquired by Roche), IONA® test (Premaitha Health), Prenatal BACs-on-BeadsTM (PerkinElmer®), PraenaTest® / PrenaTest® (LifeCodexx, a subsidiary of GATC Biotech), Prendia (Genesupport, FASTERIS, Swiss Institute for Bioinformatics), SerenityTM test (Genesis GeneticsTM) and Tranquility (Genoma, a subsidiary of ESPERITE).
2. Of the total NIPTs (commercially available / under development), 83% are designed on the basis of massively parallel sequencing / next-generation sequencing methods (MPS / NGS) for the detection of diseases under their test panels. It is worth highlighting that some developers are utilizing a novel epigenetics based approach for the development of their NIPTs.
3. The current market landscape features contributions from big pharmaceutical companies and small to mid-sized players. Established players engaged in the development of NIPTs include (in alphabetical order) BGI, Natera®, PerkinElmer®, SequenomTM (acquired by LabCorp®), Sonic Healthcare and Quest DiagnosticsTM. Small and mid-sized companies engaged in the field of NIPT include (in alphabetical order) Ariosa Diagnostics (acquired by Roche), Berry Genomics, EvolveGene, LifeCodexx (a subsidiary of GATC Biotech), NIPD Genetics, NxGen MDx, Premaitha Health and Verinata Health (acquired by Illumina®).
4. Prominent academic institutions and universities involved in the field of NIPT include (in alphabetical order) the Birmingham Women’s Hospital, Cyprus Institute of Neurology and Genetics, Murdoch Children’s Research Institute, National University of Singapore, Stanford University, Swiss Institute for Bioinformatics, The Chinese University of Hong Kong and University of Antwerp.
5. We also came across 38 advanced newborn screening tests available for the detection of a large number of disorders / deficiencies including metabolic disorders, endocrine disorders, hemoglobin disorders, congenital heart disorders and hearing disorders. Of the total advanced newborn screening tests, 66% of the tests use blood as the testing sample (categorized as basic screening tests). This is followed by advanced screening tests and comprehensive screening tests capturing a share of 16% and 10%, respectively. Nearly 8% of the newborn screening tests utilize urine as the sample and are categorized as expanded newborn screening tests.
6. Over 135 collaborations have been inked in the field of NIPT between 2011 and 2017. Although a significant proportion of these agreements focus on distribution / marketing of NIPTs to expand their access and coverage in different geographies (54%), we came across a number of product development / commercialization agreements (15%), merger / acquisition agreements (9%) and product / technology licensing agreements (8%). Several companies have entered into multiple collaborations; these include SequenomTM (24 agreements), Natera® (20 agreements), Premaitha Health (19 agreements), BGI (18 agreements), Ariosa Diagnostics (14 agreements) and Illumina® (13 agreements).
7. The NIPT market, primarily driven by increasing awareness and adoption of NIPTs, is anticipated to grow at an annualized rate of 15% between 2017 and 2027. The current market is dominated by the tests offered to expectant women belonging to high risk category, capturing 52% market share. However, by 2027, the average risk market is likely to be amongst the key drivers; we expect its share to grow from 37% in 2017 to 45% by 2027.
8. Amongst specific indications screened under NIPT test panels, chromosomal abnormalities (primarily including trisomy 21 (Down syndrome), trisomy 18 (Edward syndrome), trisomy 13 (Patau syndrome)) are likely to capture the largest share of the market in both 2017 (44%) and 2027 (56%). This is followed by sex chromosomal abnormalities, capturing a share of 24% in 2017 and 28% in 2027. These include Turner syndrome, Klinefelter syndrome, Triple X syndrome and Jacob syndrome. Microdeletion syndromes, primarily including Cri-du-chat syndrome, DiGeorge syndrome, Prader-Willi syndrome, monosomy 1p36 and Wolf-Hirschhorn syndrome, are likely to account for a share of 22% in 2017 and 14% in 2027.
9. With regard to the geographical activity, in 2017, the North America is likely to capture the maximum share (37%) followed by Europe (35%) and Asia (24%). Over the coming decade, Asian regions are likely to drive the growth resulting in a share of 29% in 2027. It is important to highlight that, within Asia, countries such as China, India, Japan, have several developers and distributors of NIPT tests, demonstrating an increasing interest in these regions.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct extensive secondary research as well as interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and sub-segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high level view on the current state of the NIPT and the newborn screening market and its likely evolution over the next decade.

Chapter 3 provides a general introduction of various types of chromosomal abnormalities and genetic disorders occurring in fetuses and newborns with information on their statistics, and the different types of genetic tests available for their detection. It outlines the concept of invasive and non-invasive prenatal testing. In addition, the chapter offers a discussion on the historical evolution of newborn screening.

Chapter 4 provides a holistic view of the NIPT and newborn screening market. It provides a comprehensive list of NIPT and newborn screening tests. The chapter includes a detailed analysis of the NIPTs based on the development stage, technology platforms, type of indications tested, stage of pregnancy and result turnaround time. In addition, it includes a detailed analysis of the newborn screening tests based on the screening type, technology platform, type of indication, period of sample collection after birth and result turnaround time. The chapter also lists the basic prenatal testing and newborn screening tests, devices, systems and technology platforms.

Chapter 5 is a compilation of key insights gained from this study. It includes a geographical coverage analysis that highlights the availability of each NIPT test in different regions across the globe, and a heat map representing the relative clinical performance of the commercially available NIPTs on the basis of sensitivity, specificity, result turnaround time and the stage of pregnancy when the test can be performed. In addition, it presents a Harvey ball analysis depicting the test panel strength on the basis of number of indications screened, and a world map to represent the geographical presence and the activity of companies involved in the field of NIPT. The chapter also includes a grid representation of the newborn screening tests, highlighting the distribution of these tests on the basis of screening type (basic newborn screening, expanded newborn screening, comprehensive newborn screening and advanced newborn screening) and the technology platforms used to design them. Additionally, it features a developer landscape of the companies involved in the field of newborn screening, distributed on the basis of the company size and geographical presence.

Chapter 6 offers a comprehensive discussion on NIPT tests, highlighting advantages and challenges associated with the development and use of these tests. The chapter features detailed company profiles of the leading players that are involved in the development of NIPT tests. Each profile includes a brief overview of the company, its financial information, funding details, product portfolio and an informed future outlook. It also includes detailed profiles of the products of these key players. Each product profile provides information on the development history, specifications, technology platform, procedure, advantages and clinical information of different products offered by the company. In addition, the chapter includes a development timeline marking the launch of the popular NIPT tests between 2011 and 2016. It also provides a commercial landscape of the most popular NIPTs on the basis of different characteristics of these tests.

Chapter 7 offers a comprehensive discussion on newborn screening. It talks about different types of next-generation newborn screening procedures. We have provided company profiles and product profiles of the key players engaged in the development of newborn screening tests. In addition, it includes brief profiles of other players involved in this field. The section also includes an elaborate discussion on the current spread of newborn screening programs established in various countries across the globe to provide proper medical care to newborns.

Chapter 8 provides details on the other diagnostic tests / services available for genetic testing in newborns and fetuses; these include carrier testing / preconception care, preimplantation genetic testing (PGT) (preimplantation genetic diagnosis / screening (PGD / PGS)), genetic counselling and direct to consumer (DTC) genetic testing services. We have provided a brief overview of these tests / services, highlighting their general procedure / workflow, indications being evaluated and their indicative development pipeline.

Chapter 9 features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in both NIPT and newborn screening markets. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this domain.

Chapter 10 highlights the market forecast and sizing of the overall NIPT and newborn screening markets. This chapter discusses, in detail, the parameters that are likely to influence the evolution of these markets. It features detailed insights on the likely evolution of the NIPT market for different patient risk group segments (high risk, average risk and low risk). The chapter highlights the likely distribution of the market across North America (the US, Canada and Mexico), Europe (France, Germany, Italy, Spain, the UK and rest of Europe), Asia (Japan, China and India) and rest of the world. It also presents a detailed market segmentation by the key indications, stage of pregnancy when the tests can be performed and share of individual NIPT tests. In addition, the chapter offers a high-level view on the upcoming newborn screening market across the globe.

Chapter 11 summarizes the overall report and provides a recap of the key takeaways from the study. It also presents our independent opinion on the future of both NIPT and newborn screening market based on the research and analysis described in the previous chapters.

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in these fields. We have presented the insights provided to us by Jim Patterson (Vice President, Sales and Marketing North America, EvolveGene®), Osama Fikry (Metabolic and Diagnostic Head, NewBridge Pharmaceuticals) and Silke Arndt (Medical Scientist and NGS Manager, Inqaba Biotec).
Chapter 13 illustrates a detailed analysis on the survey conducted for gaining a deeper understanding on the nature of products and services offered by the companies involved in NIPT and / or newborn screening fields.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
1. 23andMe
2. A*STAR’s Institute of Microelectronics (IME)
3. AB SCIEX
4. Abbott Molecular
5. Abbott Pathology
6. Academy of Finland
7. Accela
8. Acibadem Healthcare Group
9. American College of Medical Genetics and Genomics (ACMG)
10. American Congress of Obstetrics and Gynecology (ACOG)
11. Adgenix
12. Advance Medical
13. Advanced Liquid Logic
14. Aegis Sciences
15. Aetna
16. Affymetrix
17. Agena Bioscience
18. Agilent Technologies
19. AL Borg Medical Laboratories
20. Alafi Capital
21. Alloy Ventures
22. Alpert Medical School, Brown University
23. Amarey Nova Medical Group
24. Amedes
25. American Association for Laboratory Accreditation (A2LA)
26. American Association of Blood Banks (AABB)
27. American Clinical Laboratory Association (ACLA)
28. American Medical Association (AMA)
29. American Hospital of Paris
30. Ani Biotech
31. Ani Labsystems
32. Annoroad Gene Technology
33. Anthem Blue Cross and Blue Shield
34. Antisel
35. APHL - Association of Public Health Laboratories
36. Applied Spectral Imaging (ASI)
37. Arabian Genetic Testing Company (AGTC)
38. ARCEDI Biotech
39. ARCHIMEDlife
40. Ariosa Diagnostics
41. ARUP Laboratories
42. Asia Pacific Capital Management
43. Asper Biotech
44. Astoria-Pacific
45. Atlas Genomics
46. Australian Clinical Lab
47. AutoGenomics
48. Baby Genes
49. Baebies
50. Bangkok Cytogenetics Center
51. Bangkok R.I.A LAB
52. Basetra
53. Baylor Genetics
54. BEAZ
55. Berry Genomics
56. BGI
57. BGI Agriculture
58. BGI College
59. BGI Diagnosis
60. BGI Forensics
61. BGI Genomics
62. BGI Health
63. BGI Manufacturing
64. BGI Research
65. BGI Tech
66. Big Belli
67. BioGen Medical
68. Biomnis
69. BioPoint
70. Bio-Rad Laboratories
71. BioReference Laboratories
72. Bioscience Genomics
73. Bioscience Institute
74. Birmingham Women’s Hospital
75. BlueGenome
76. Bome Sanayi Ürünleri Dış Ticaret
77. Brown University
78. CairoGene
79. California Department of Health
80. CAPP Medical
81. Catholic Health Initiatives (CHI)
82. Cell Genetics
83. CellScape
84. Cenata
85. Center for Human Genetics and Laboratory Diagnostics
86. Center for Medical Genetics, Houston
87. Center for Medical Genomics (CMG)
88. Centers for Disease Control and Prevention (CDC)
89. Centers for Medicare and Medicaid Services (CMS)
90. CENTOGENE
91. CENTOGENE ARABIA
92. Centrum Badan DNA Group
93. CGC Genetics
94. Children’s Mercy Hospital, Kansas
95. China National GeneBank
96. China’s National Health and Family Planning Commission
97. Chinese Food and Drug Administration
98. Cigna
99. Cinven
100. Claremont Creek Ventures
101. Clarity Medical Systems
102. CML Healthcare Collection Centers
103. CMS Computers
104. Coalition for Access to Prenatal Screening (CAPS)
105. College of American Pathologists (CAP)
106. Color Genomics
107. CombiMatrix
108. Commission for Office Laboratory Accreditation
109. Complete Genomics
110. Cooper SurgicalTM
111. CooperGenomics
112. Cordlife Group
113. Cordlife Sciences
114. Council of Regional Networks for Genetic Services
115. Counsyl
116. Cypher Genomics
117. Cyprus Institute of Neurology and Genetics
118. Cytogenomic External Quality Assessment Service (CEQAS)
119. DaAn Gene
120. Danaher Corporation
121. DASA Group
122. Datar Genetics
123. DBS Systems
124. deCODEme genetics
125. Department of Health and Human Services (HHS), US
126. Devyser
127. DiagCor
128. Diputación de Bizkaia
129. DNA Diagnostics Center (DDC)
130. Domain Associates
131. Dorevitch Pathology
132. Douglass Hanly Moir Pathology
133. Dr Lal PathLabs
134. DrGene
135. Eastern Biotech & Life Sciences
136. Echevarne
137. EGL Genetic Diagnostics
138. ELAN Group
139. ELIPS
140. Elite PharmaLab Solutions
141. Elucigene Diagnostics
142. Emory Genetic Diagnostics
143. Emory University's School of Medicine
144. Empireo Molecular Diagnostic
145. Eone Life Science Institute and Diagnomics
146. EONE-DIAGNOMICS Genome Center (EDGC)
147. ePlanet Ventures
148. ESPERITE
149. Eurofins Clinical Genetics India (ECGI)
150. Eurofins Scientific
151. European Diagnostics Services Group
152. European Molecular Genetics Quality Network (EMQN)
153. EvolveGene®
154. Famina Healthcare
155. FASTERIS
156. Food and Drug Administration (FDA)
157. Fetal Medicine Foundation
158. Fidelity Growth
159. Finnish Funding Agency for Innovations
160. Flatiron Health
161. Fleury Medicina e Saúde (Fleury Group)
162. Florida Agency for Health Care and Administration
163. Foundation for the Accreditation of Cellular Therapy (FACT)
164. Foundation Medicine
165. Founders Fund
166. Franklin Templeton Investments
167. Federal Trade Commission (FTC)
168. GATC Biotech
169. GENDIA (GENetic DIAgnostic Network)
170. Gene by Gene
171. GeneDx
172. GeneMetrics
173. Geneplus
174. GeneProof
175. Genesis GeneticsTM
176. Genesis GeneticsTM South Africa
177. GeneSupport
178. Genetadi Biotech
179. GeneTech
180. GeneTech Kazusa Laboratory
181. Genetic Associates
182. Genesis Genetics International
183. GeNext
184. Genia Technologies
185. GENNET
186. Genoks
187. GenoLogics Life Sciences Software
188. Genoma
189. Genomed
190. Genomic Diagnostics
191. Genomics For life
192. Genomi-k
193. Genomill Health
194. GenomixLAB
195. Genopharm
196. Genos
197. GenPath Diagnostics
198. Genpharm Services
199. Gentica
200. GENYCA
201. GigaScience
202. GN Otometrics
203. Good Start Genetics
204. Google India
205. GRAIL
206. GTL DNA
207. Harmony Partners
208. Headland Capital
209. Health Professional Council of South Africa (HPCSA)
210. Health Resources and Services Administration (HRSA)
211. HealthCor Partners
212. Helicos BioSciences
213. Helix Holdings
214. HemaXis
215. HemoFlux
216. Henry Schein Medical
217. Hitech Diagnostic Centre
218. Hive Technologies
219. Hologic
220. Hong Kong Molecular Pathology Diagnostic Centre
221. Hong Kong Screening Centre
222. Hospital Israelita Albert Einstein
223. Humana
224. IBL International
225. Icahn School of Medicine at Mount Sinai
226. Integrated Gulf Biosystems
227. iGene Diagnostics
228. IGENOMIX
229. Igentify
230. iLife Discoveries
231. Illumina®
232. IMUA Family Services
233. India Value Fund Advisors (IVFA)
234. Indian Department of Biotechnology
235. INEX (Innovations Exchange)
236. InKaryo
237. Innermost Healthcare
238. Innovation Elite
239. Inova Translational Medical Institute
240. Inqaba Biotec
241. Insight Medical Genetics
242. Institute of Medical Genetics, College of Life Science, Sichuan University
243. Integrated Genetics
244. Intercare Salubrity
245. International 22q11.2 Foundation
246. InterWest Health
247. Invitae
248. IQuum
249. Isis Innovation
250. International Society for Prenatal Diagnosis (ISPD)
251. Istenhegyi Centre for Genetic Diagnostics
252. IVF Michigan
253. IVIOMICS
254. Jennison Associates
255. Joaquim Chaves Group
256. Joint Commission on Accreditation of Healthcare Organizations
257. Just4Me Genetics
258. K3
259. Kalorama Information
260. Kansas City School of Medicine, University of Missouri
261. Kapa Biosystems and Signature Diagnostics
262. KellBenx
263. Knome
264. Knox Audiology
265. LABCO Quality Diagnostics
266. Laboratoire Cerba
267. Laboratory Corporation of America® Holding
268. LaboSud
269. Labsystems Diagnostics
270. Laverty Pathology
271. Li Ka Shing Institute of Health Sciences
272. Life TechnologiesTM
273. LifeCell
274. LifeCodexx
275. LifeGlobal Group
276. LifeLabs Genetics
277. Lightspeed Venture Partners
278. Lilac Insights
279. Macrogen
280. Magee-Women’s Hospital of UPMC Center for Medical Genetics
281. Mahidol University
282. MAICO Diagnostics
283. Malaysia Fetal Genome
284. MAP Diagnostics
285. Mapmygenome™
286. Maryland Department of Health and Mental Hygiene
287. Masimo® Corporation
288. Maternal and Child Health Bureau (MCHB)
289. Maverix Biomics
290. Mayo Medical Laboratories
291. McKesson Medical-Surgical
292. MedGen
293. MedGenome
294. Medical Chambers Kensington
295. Medical Genetics Laboratory, Baylor College of Medicine
296. Medical Genomics
297. Medisupport
298. MedLab Asia Group
299. MEDNAX
300. Meritech Capital Partners
301. Metis Genetics
302. Metropolis
303. Ministry of Science and Technology, India
304. MIT Angels
305. Mohr Davidow Ventures
306. Molecular Devices
307. Monobind
308. MOR Institute for Medical Data
309. Mount Sinai Genetic Testing Laboratory
310. MSA Safety
311. MultiCare
312. Multigene Diagnostics
313. MultiPlan
314. Multiplicom
315. Murdoch Children’s Research Institute
316. MyGenetx
317. MyMedLab
318. Myraqa
319. National Accreditation Board for Testing and Calibration Laboratories (NABL)
320. Natera®
321. National Health and Family Planning Commission (NHFPC)
322. National Institutes of Health (NIH)
323. National Newborn Bloodspot Screening Laboratory (NNBSL), Temple Street Children’s University Hospital
324. National Society of Genetic Counselors
325. National University of Singapore (NUS)
326. Natus® Medical
327. Navigene Genetic Science
328. NeoGen Labs
329. NEUROSPEC
330. New Born Solutions
331. New York Department of Health
332. New York State Laboratory
333. Newborn Foundation
334. NewBorn Gene ID
335. NewBridge Pharmaceuticals
336. Next Biosciences
337. NextBio
338. NextlineTM Diagnostics
339. NicView
340. NIMGenetics
341. NIPD Genetics
342. North-West University
343. Novogene
344. NX Prenatal
345. NxGen MDx
346. Onsite Neonatal Partners
347. OPKO Health
348. OrbiMed
349. Otometrics
350. Oxford Biosystems
351. Oxford Gene Technology (OGT)
352. OZ Systems
353. PacGenomics
354. Pacific Rim Pathology
355. Padtan
356. Paperboy Ventures
357. Parabase Genomics
358. Paragon Genomics
359. Pathology Associates Medical Laboratories (PAML)
360. Pathway Genomics
361. Pediatrix Medical Group
362. Pennsylvania Department of Health
363. Perinatal Quality Foundation (PQF)
364. PerkinElmer® Genetics
365. Personal Genomics
366. Phoebus Genetics
367. Pink Newborn Services
368. PlexBio
369. Positive Bioscience
370. Postnatal Peace
371. Pregnicare
372. Premaitha Health
373. Prenatal Diagnosis Centers (PDC)
374. Prenatal Genetics
375. Prenetics
376. Pressure BioSciences
377. PreventiNe Life Care
378. Previvo Genetics
379. Primary Health Care
380. Profema
381. Progenesis
382. Progenitest
383. Progenity
384. Pronto Diagnostics
385. ProPath
386. Providence Health & Services
387. QML Pathology
388. Quantum Diagnostics
389. Quest Diagnostics
390. RA Capital Management
391. Ramathibodi Hospital, Thailand
392. Rarecells
393. Ravgen
394. Recombine
395. Red Rock Fertility Center
396. Reproductive Genetic Innovations (RGI)
397. Reprogenetics
398. Rhode Island Department of Health
399. Roche
400. Rothschild Ventures Asia
401. S.R.L
402. Safembryo
403. Sagentia
404. Science Labs NIPT
405. ScreenCell
406. Sebia
407. Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC)
408. Secuvita
409. Sengenics
410. Seoul National University Hospital (SNUH)
411. SequenomTM
412. Sequenom Center for Molecular Medicine (SCMM)
413. Sequoia Capital
414. SeraCare Life Sciences
415. Servicios Genéticos OriGen
416. Shenz Medical Center
417. Shenzhen BGI Unicare Clinic
418. Shenzhen Chi-Next Exchange
419. Shimadzu Corporation
420. Sichuan University
421. Siemens
422. Silicon Biosystems
423. Singapore Angel Network
424. Singlera Genomics
425. Siriraj Hospital, Thailand
426. Sistemas Genómicos
427. SNPgenomics
428. Sofinnova Ventures
429. SOFIVA Genomics
430. Solstas Lab Partners
431. Sonic Healthcare
432. Sophia Genetics
433. Source BioScience
434. SouthGenetics
435. SpOtOn Clinical Diagnostics
436. Srushti Hospital, India
437. St. George’s University
438. St. George's Hospital
439. Stanford University
440. StartUp Health
441. Sutter Hill Ventures
442. Swiss Institute for Bioinformatics
443. SXE Ventures
444. Synapse Diagnostics
445. SYNERGY Medical Systems
446. SYNLAB
447. Tasmanian Medical Laboratories
448. TATAA Biocenter
449. Teva Pharmaceutical
450. Thailand Center of Excellence for Life Sciences (TCELS)
451. The Chinese University of Hong Kong
452. The Doctors Laboratory (TDL)
453. The Fetal Medicine Centre, London
454. The Society for Maternal-Fetal Medicine (SMFM)
455. Thermo Fisher Scientific
456. This Is My
457. TMC Life Sciences
458. TOMA Advanced Biomedical Assays
459. Tor Vergata University, Rome
460. Translational Health Science Technology Institute (THSTI)
461. Trivitron Healthcare
462. TrovaGene
463. Tulip Diagnostics
464. Tute Genomics
465. UK Centre of Excellence
466. UK NEQAS
467. UNIConnect
468. Unilabs
469. United Overseas Bank Venture Management
470. UnitedHealthcare
471. University of Antwerp
472. University of California
473. University of Hong Kong
474. University of Rochester
475. University of Turku
476. University of Washington
477. Vanadis Diagnostics
478. Vantari Genetics
479. Venrock
480. Verinata Health
481. Victorian Clinical Genetics Services (VCGS)
482. Viollier
483. Virion-Serion
484. Visional Medical
485. Visunex Medical Systems
486. Vivosonic
487. Walnut Venture Associates
488. West Midlands Regional Genetics Laboratory
489. Western Diagnostic Pathology
490. Wolfson Institute of Preventive Medicine
491. Women and Infant's Hospital, Rhode Island
492. World Health Organization (WHO)
493. WuXi AppTec (WuXi Biologics)
494. Xcelom
495. Yale School of Medicine
496. Yale Women and Children’s Center
497. Yikon Genomics
498. Yourgene Bioscience
499. ZenTech


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Importance of Disease Detection: Screening Versus Diagnosis
3.3. Genetic Abnormalities: An Introduction
3.3.1. Classification of Genetic Disorders
3.3.1.1. Chromosomal Abnormalities
3.3.1.2. Single Gene Disorders
3.3.1.3. Teratogenic Problems
3.3.1.4. Complex / Multifactorial Problems
3.3.2. Statistics and Epidemiology of Genetic Disorders
3.3.3. Common Genetic Disorders: Causes and Symptoms
3.4. Genetic Tests: Importance in Prenatal and Neonatal Care
3.5. Prenatal Genetic Testing: A Detailed Overview
3.5.1. Conventional Methods of Prenatal Testing
3.5.1.1. Maternal Serum Screening
3.5.1.2. Ultrasonography
3.5.1.3. Invasive Confirmatory Tests
3.5.1.3.1. Amniocentesis
3.5.1.3.2. Chorionic Villus Sampling (CVS)
3.5.1.4. Fetal Cells in Maternal Blood (FCMB)
3.5.2. Non-Invasive Prenatal Testing (NIPT)
3.6. The Concept of Newborn Screening
3.6.1. Evolution of Newborn Screening
3.7. Ethical Issues Related to Prenatal Testing and Newborn Screening
4. NIPT AND NEWBORN SCREENING: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. NIPT: Development Landscape
4.2.1. NIPT: Distribution by Stage of Development
4.2.2. NIPT: Distribution by Technology Platforms
4.2.3. NIPT: Distribution by Type of Indication
4.2.4. NIPT: Distribution by Stage of Pregnancy
4.2.5. NIPT: Distribution by Result Turnaround Time
4.3. NIPT: Technology Platforms
4.4. Prenatal Testing: Other Initiatives
4.5. Newborn Screening: Development Landscape
4.5.1. Newborn Screening: Distribution by Screening Type
4.5.2. Newborn Screening: Distribution by Technology Platforms
4.5.3. Newborn Screening: Distribution by Type of Indication
4.5.4. Newborn Screening: Distribution by Period of Sample Collection After Birth
4.5.5. Newborn Screening: Distribution by Result Turnaround Time
4.6. Newborn Screening: Other Initiatives
5. NIPT AND NEWBORN SCREENING: KEY INSIGHTS
5.1. Chapter Overview
5.2. NIPTs: Distribution by Geographical Coverage
5.3. Commercialized NIPTs: A Competitive Heat Map Analysis for Clinical Efficiency
5.4. NIPTs: Harvey Ball Analysis for Test Panel Strength
5.5. NIPTs: Geographical Distribution of Industry Players
5.6. Newborn Screening Grid Analysis: Distribution by Screening Type and Technology Platforms
5.7. Newborn Screening Developer Landscape: Distribution by Company Size and Geography
6. PRENATAL TESTING: FOCUS ON NIPT
6.1. Chapter Overview
6.2. Emergence of NIPT
6.3. NIPT Key Players: Company Profiles
6.3.1. Ariosa Diagnostics (Acquired by Roche)
6.3.1.1. Company Introduction
6.3.1.2. Financial Information
6.3.1.3. Product Portfolio
6.3.1.3.1. Harmony® Test
6.3.1.3.1.1. Product Overview and Development History
6.3.1.3.1.2. Product Specifications
6.3.1.3.1.3. Technology Overview
6.3.1.3.1.4. Procedure and Interpretation of Results
6.3.1.3.1.5. Advantages
6.3.1.3.1.6. Clinical Information

6.3.1.4. Future Outlook
6.3.2. BGI
6.3.2.1. Company Introduction
6.3.2.2. Financial Information
6.3.2.3. Product Portfolio
6.3.2.3.1. NIFTY® Test
6.3.2.3.1.1. Product Overview and Development History
6.3.2.3.1.2. Product Specifications
6.3.2.3.1.3. Technology Overview
6.3.2.3.1.4. Procedure and Interpretation of Results
6.3.2.3.1.5. Advantages
6.3.2.3.1.6. Clinical Information
6.3.2.4. Future Outlook
6.3.3. Natera®
6.3.3.1. Company Introduction
6.3.3.2. Financial Information
6.3.3.3. Product Portfolio
6.3.3.3.1. Panorama® Test
6.3.3.3.1.1. Product Overview and Development History
6.3.3.3.1.2. Product Specifications
6.3.3.3.1.3. Technology Overview
6.3.3.3.1.4. Procedure and Interpretation of Results
6.3.3.3.1.5. Advantages
6.3.3.3.1.6. Clinical Information
6.3.3.4. Future Outlook
6.3.4. SequenomTM (Acquired by LabCorp®)
6.3.4.1. Company Introduction
6.3.4.2. Financial Information
6.3.4.3. Product Portfolio
6.3.4.3.1. MaterniT® GENOME
6.3.4.3.1.1. Product Overview and Development History
6.3.4.3.1.2. Product Specifications
6.3.4.3.1.3. Procedure and Interpretation of Results
6.3.4.3.1.4. Advantages
6.3.4.3.1.5. Clinical Information
6.3.4.3.2. VisibiliTTM Test
6.3.4.3.2.1. Product Overview and Development History
6.3.4.3.2.2. Product Specifications
6.3.4.3.2.3. Procedure and Interpretation of Results
6.3.4.3.2.4. Advantages
6.3.4.3.2.5. Clinical Information
6.3.4.3.3. MaterniT21® PLUS Test
6.3.4.3.3.1. Product Overview and Development History
6.3.4.3.3.2. Product Specifications
6.3.4.3.3.3. Technology Overview
6.3.4.3.3.4. Procedure and Interpretation of Results
6.3.4.3.3.5. Advantages
6.3.4.3.3.6. Clinical Information
6.3.4.3.4. SensiGene® RhD Test
6.3.4.3.4.1. Product Overview and Development History
6.3.4.3.4.2. Product Specifications
6.3.4.3.4.3. Technology Overview
6.3.4.3.4.4. Procedure and Interpretation of Results
6.3.4.3.4.5. Advantages
6.3.4.3.4.6. Clinical Information
6.3.4.3.5. NextViewTM Array Diagnostic Test Platform
6.3.4.3.5.1. Product Overview and Development History
6.3.4.3.5.2. Product Specifications
6.3.4.4. Future Outlook
6.3.5. Verinata Health (Acquired by Illumina®)
6.3.5.1. Company Introduction
6.3.5.2. Financial Information
6.3.5.3. Product Portfolio
6.3.5.3.1. Verifi® Prenatal Test / InformaSeqSM
6.3.5.3.1.1. Product Overview and Development History
6.3.5.3.1.2. Product Specifications
6.3.5.3.1.3. Technology Overview
6.3.5.3.1.4. Procedure and Interpretation of Results
6.3.5.3.1.5. Advantages
6.3.5.3.1.6. Clinical Information
6.3.5.4. Future Outlook
6.4. Popular NIPTs: A Detailed Comparison
6.5. NIPT: Regulatory Landscape
6.6. NIPT: Future Outlook
7. NEWBORN SCREENING: DETAILED OUTLOOK
7.1. Chapter Overview
7.2. Newborn Screening: Introduction and Classification
7.2.1. Classification of Newborn Screening Tests: By Sample Type
7.2.2. Classification of Newborn Screening Tests: By Period of Sample Collection After Birth
7.2.3. Classification of Newborn Screening: By Patient Risk Group
7.3. Technological Advances in Newborn Screening
7.4. Newborn Screening Key Players: Company Profiles
7.4.1. BGI
7.4.1.1. Company Introduction
7.4.1.2. Financial Information
7.4.1.3. Product Portfolio
7.4.1.3.1. NOVATM Newborn Genetic Test
7.4.1.3.1.1. Product Overview
7.4.1.3.1.2. Product Specifications and Test Methodology
7.4.1.3.2. NOVATM Metabolic Disease Screening
7.4.1.3.2.1. Product Overview
7.4.1.3.2.2. Product Specifications and Test Methodology
7.4.1.4. Future Outlook
7.4.2. Cordlife Group
7.4.2.1. Company Introduction
7.4.2.2. Financial Information
7.4.2.3. Product Portfolio
7.4.2.3.1. MetaScreenTM
7.4.2.3.1.1. Product Overview
7.4.2.3.1.2. Product Specifications and Test Methodology
7.4.2.4. Future Outlook
7.4.3. Genomi-k
7.4.3.1. Company Introduction
7.4.3.2. Product Portfolio
7.4.3.2.1. Audi-k® Service
7.4.3.2.1.1. Product Overview
7.4.3.2.1.2. Product Specifications and Test Methodology
7.4.3.2.2. Cardi-k® Service
7.4.3.2.2.1. Product Overview
7.4.3.2.2.2. Product Specifications and Test Methodology
7.4.3.2.3. Tami-k® Service
7.4.3.2.3.1. Product Overview
7.4.3.2.3.2. Product Specifications and Test Methodology
7.4.4. Genetadi Biotech
7.4.4.1. Company Introduction
7.4.4.2. Product Portfolio
7.4.4.2.1. Neonatal-One Plus
7.4.4.2.1.1. Product Overview
7.4.4.2.1.2. Product Specifications and Test Methodology
7.4.4.3. Future Outlook
7.4.5. NextlineTM Diagnostics
7.4.5.1. Company Introduction
7.4.5.2. Product Portfolio
7.4.5.2.1. BIRTHRIGHT
7.4.5.2.1.1. Product Overview
7.4.5.2.1.2. Product Specifications and Test Methodology
7.4.5.3. Future Outlook
7.4.6. Parabase Genomics
7.4.6.1. Company Introduction
7.4.6.2. Financial Information
7.4.6.3. Product Portfolio
7.4.6.3.1. NewbornDxTM Test
7.4.6.3.1.1. Product Overview
7.4.6.3.1.2. Product Specifications and Test Methodology
7.4.6.3.2. NewbornDxTM HL
7.4.6.3.2.1. Product Overview
7.4.6.3.2.2. Product Specifications and Test Methodology
7.4.6.4. Future Outlook
7.4.7. PerkinElmer® Genetics
7.4.7.1. Company Introduction
7.4.7.2. Financial Information
7.4.7.3. Product Portfolio
7.4.7.3.1. StepOne® Newborn Screening Panel
7.4.7.3.1.1. Product Overview
7.4.7.3.1.2. Product Specifications and Test Methodology
7.4.7.4. Future Outlook
7.4.8. SouthGenetics
7.4.8.1. Company Introduction
7.4.8.2. Product Portfolio
7.4.8.2.1. BabyGenesTM
7.4.8.2.1.1. Product Overview
7.4.8.2.1.2. Product Specifications and Test Methodology
7.4.8.3. Future Outlook
7.4.9. Other Prominent Players
7.4.9.1. AB SCIEX
7.4.9.2. Aegis Sciences
7.4.9.3. ARCHIMEDlife
7.4.9.4. Baby Genes
7.4.9.5. CENTOGENE
7.4.9.6. EGL Genetic Diagnostics
7.4.9.7. GeneTech
7.4.9.8. iLife Discoveries
7.4.9.9. Macrogen
7.4.9.10. MapmygenomeTM
7.4.9.11. Navigene Genetic Science
7.4.9.12. NeoGen Labs
7.4.9.13. Next Biosciences
7.4.9.14. NIMGenetics
7.4.9.15. Pediatrix Medical Group
7.4.9.16. PreventiNe Life Care
7.4.9.17. Synapse Diagnostics
7.4.9.18. Trivitron Healthcare
7.5. Newborn Screening Programs: Government Initiatives
7.5.1. Asia Pacific
7.5.2. Europe
7.5.3. Latin America
7.5.4. Middle East and North Africa (MENA)
7.5.5. North America
7.6. Newborn Screening: Future Outlook
8. OTHER ASSOCIATED TESTS AND SERVICES
8.1. Chapter Overview
8.2. Carrier Testing / Preconception Care
8.2.1. Carrier Testing / Preconception Care: An Overview
8.2.2. Carrier Testing / Preconception Care: Commercialized Tests
8.3. Preimplantation Genetic Diagnosis / Screening (PGD / PGS)
8.3.1. PGD / PGS: An Overview
8.3.2. PGD / PGS: Commercialized Tests
8.4. Genetic Counseling and Direct to Customer (DTC) Genetic Testing Services
9. RECENT COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. NIPT: Recent Collaborations
9.3.1. Recent Collaborations: Distribution by Year
9.3.2. Recent Collaborations: Distribution by Type of Model
9.3.3. Recent Collaborations: Most Active Companies
9.4. Newborn Screening: Recent Collaborations
9.4.1. Recent Collaborations: Distribution by Year
9.4.2. Recent Collaborations: Distribution by Type of Model
9.4.3. Recent Collaborations: Most Active Companies
10. NIPT AND NEWBORN SCREENING: MARKET SIZING AND FORECAST
10.1. Chapter Overview
10.2. NIPT: Scope and Forecast Methodology
10.3. NIPT: Forecast Assumptions
10.3.1. Patient Population
10.3.2. Price of Test
10.3.3. Adoption / Penetration Rate
10.4. NIPT: Forecast Projections, 2017-2027
10.4.1. NIPT Market, 2017-2027
10.4.2. NIPT Market: Distribution by Patient Risk Group
10.4.3. NIPT Market: Distribution by Geography
10.4.3.1. NIPT Market in North America
10.4.3.2. NIPT Market in Europe
10.4.3.3. NIPT Market in Asia
10.4.3.4. NIPT Market in Rest of the World
10.4.4. NIPT Market: Distribution by Indication
10.4.5. NIPT Market: Distribution by Stage of Pregnancy
10.4.6. NIPT Market: Distribution by Share of Individual NIPTs
10.5. Newborn Screening: Opportunity Analysis
11. CONCLUSION
11.1. Prenatal Testing and Newborn Screening Have Emerged as Popular Diagnostic Tools for Identification of Genetic Abnormalities in Fetuses and Newborns
11.2. Continuous Innovation has Led to the Development of NIPTs and Advanced Newborn Screening Tests
11.3. These Novel Screening Methods Cater to a Wide Spectrum of Disease Indications
11.4. The Interest has Steadily Risen with the Presence of Multiple Start-ups Across Different Geographies
11.5. The Growing Number of Partnerships are Indicative of a Lucrative Future Potential
11.6. Despite the Ethical Challenges in Developing Countries, the NIPT Market is Likely to Prosper Significantly in the Long Term
11.7. While the Newborn Screening Market is Still Evolving with Advanced Techniques, the NIPT Diagnostic Market is Already Witnessing an Accelerated Growth
12. INTERVIEW TRANSCRIPTS
12.1. Chapter Overview
12.2. Jim Patterson, Vice President, Sales and Marketing North America, EvolveGene®
12.3. Osama Fikry, Metabolic and Diagnostic Head, NewBridge Pharmaceuticals
12.4. Silke Arndt, Medical Scientist and NGS Manager, Inqaba Biotec
13. SURVEY ANALYSIS
13.1. Chapter Overview
13.2. Seniority Level of Respondents
13.3. Focus Area of the Company
13.4. Type of Lead Product(s)
13.5. Purpose of Lead Product(s)
13.6. Commercial Availability of Lead Product(s)
13.7. Likely Market Size
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Genetic Disorders: Categories
Figure 3.2 Chromosomal Abnormalities: Numerical and Structural Disorders
Figure 3.3 Genetic Disorders in Fetuses
Figure 3.4 Genetic Disorders in Newborns
Figure 3.5 Chromosomal Abnormalities: Distribution by Type
Figure 3.6 Common Causes of Deaths in Newborns
Figure 3.7 Genetic Tests in Prenatal and Neonatal Care
Figure 3.8 Genetic Testing: Benefits and Drawbacks
Figure 3.9 Reasons for Prenatal Testing
Figure 3.10 Evolution of Prenatal Testing
Figure 3.11 Conventional Prenatal Tests in Different Stages of Pregnancy
Figure 3.12 Maternal Serum Screening Tests: Available Options
Figure 3.13 Reasons to Perform Ultrasound at Various Stages in Pregnancy
Figure 3.14 Amniocentesis: General Procedure
Figure 3.15 Newborn Screening: Components
Figure 3.16 Newborn Screening: Key Milestones
Figure 4.1 NIPT: Distribution by Stage of Development
Figure 4.2 NIPT: Distribution by Technology Platforms
Figure 4.3 NIPT: Distribution by Type of Indication
Figure 4.4 NIPT: Distribution by Chromosomal Abnormalities
Figure 4.5 NIPT: Distribution by Sex Chromosomal Abnormalities
Figure 4.6 NIPT: Distribution by Microdeletion Syndromes
Figure 4.7 NIPT: Distribution by Stage of Pregnancy
Figure 4.8 NIPT: Distribution by Result Turnaround Time
Figure 4.9 Newborn Screening: Distribution by Screening Type
Figure 4.10 Newborn Screening: Distribution by Technology Platforms
Figure 4.11 Newborn Screening: Distribution by Type of Indication
Figure 4.12 Newborn Screening: Distribution by Period of Sample Collection After Birth
Figure 4.13 Newborn Screening: Distribution by Result Turnaround Time
Figure 5.1 NIPTs: Categorization by Heat Map Analysis
Figure 5.2 NIPTs: Geographical Distribution of Industry Players
Figure 5.3 Newborn Screening Grid Analysis: Distribution by Screening Type and Technology Platforms
Figure 5.4 Newborn Screening Developer Landscape: Distribution by Company Size and Geography
Figure 6.1 NIPTs: Key Objectives
Figure 6.2 NIPT Tests: Launch Timeline
Figure 6.3 Harmony® Test: Steps of Operation
Figure 6.4 BGI: Product Portfolio
Figure 6.5 NIFTY® Test: Key Milestones
Figure 6.6 NIFTY® Test: Eligible Patient Population
Figure 6.7 NIFTY® Test: Steps of Operation
Figure 6.8 Natera®: Annual Revenues, 2013-Q1 2017 (USD Million)
Figure 6.9 Natera®: Product Portfolio
Figure 6.10 Panorama® Test: Eligible Patient Population
Figure 6.11 Panorama® Test: Steps of Operation
Figure 6.12 SequenomTM: Evolution of the NIPT Portfolio
Figure 6.13 SequenomTM: Annual Revenues, 2011-Q1 2016 (USD Million)
Figure 6.14 SequenomTM: Product Portfolio
Figure 6.15 Verifi® Prenatal Test: Eligible Patient Population
Figure 6.16 Verifi® Prenatal Test: Steps of Operation
Figure 7.1 Newborn Screening: Modes of Operation
Figure 7.2 NOVATM Newborn Genetic Test: Eligible Patient Population
Figure 7.3 NOVATM Newborn Genetic Test: Steps of Operation
Figure 7.4 Cordlife Group: Annual Revenues, 2012-2016 (USD Million)
Figure 7.5 Cordlife Group: Product Portfolio
Figure 7.6 Genomi-k: Product Portfolio
Figure 7.7 PerkinElmer®: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 7.8 Newborn Screening Programs: Current Geographical Spread
Figure 8.1 Carrier Testing: General Procedure
Figure 8.2 Carrier Testing: Recessive Disorders Inheritance
Figure 8.3 Carrier Testing: Clinical Benefits
Figure 8.4 Types of Predictive Testing
Figure 8.5 PGD: General Procedure
Figure 8.6 PGD: Most Common Types of Genetic Disorders
Figure 8.7 Purpose of Opting for Genetic Counseling
Figure 8.8 Reasons for Opting for Genetic Counseling
Figure 8.9 Essential Components of Genetic Counseling
Figure 8.10 Types of Genetic Counseling Services
Figure 9.1 Recent Collaborations in NIPT: Distribution by Year
Figure 9.2 Recent Collaborations in NIPT: Distribution by Type of Model
Figure 9.3 Recent Collaborations in NIPT: Most Active Players
Figure 9.4 Recent Collaborations in Newborn Screening: Distribution by Year
Figure 9.5 Recent Collaborations in Newborn Screening: Distribution by Type of Model
Figure 9.6 Recent Collaborations in Newborn Screening: Most Active Players
Figure 10.1 NIPT Market (2017-2027): Base Scenario (USD Billion)
Figure 10.2 NIPT Market (2017-2027): Distribution by Patient Risk Group, Base Scenario (USD Billion)
Figure 10.3 NIPT Market: Share by Patient Risk Groups, 2017, 2027 (USD Billion, %)
Figure 10.4 NIPT Market (2017-2027): Distribution by Geography, Base Scenario (USD Billion)
Figure 10.5 NIPT Market (2017-2027): Distribution by Geography, Base Scenario (Test Volume, Million)
Figure 10.6 NIPT Market: Share by Geography, 2017, 2027 (%)
Figure 10.7 NIPT Market in North America (2017-2027): Base Scenario (USD Billion)
Figure 10.8 NIPT Market in North America (2017-2027): Base Scenario (Test Volume, Million)
Figure 10.9 NIPT Market in Europe (2017-2027): Base Scenario (USD Billion)
Figure 10.10 NIPT Market in Europe (2017-2027): Base Scenario (Test Volume, Million)
Figure 10.11 NIPT Market in Asia (2017-2027): Base Scenario (USD Billion)
Figure 10.12 NIPT Market in Asia (2017-2027): Base Scenario (Test Volume, Million)
Figure 10.13 NIPT Market in Rest of the World (2017-2027): Base Scenario (USD Billion)
Figure 10.14 NIPT Market in Rest of the World (2017-2027): Base Scenario (Test Volume, Million)
Figure 10.15 NIPT Market: Share by Indication, 2017, 2027 (%)
Figure 10.16 NIPT Market: Share by Stage of Pregnancy, 2017 (%)
Figure 10.17 NIPT Market: Share by Individual NIPTs, 2017 (%)
Figure 11.1 Overall NIPT Market (USD Billion), 2017, 2022 and 2027
Figure 13.1 Survey Analysis: Distribution by Type of Company
Figure 13.2 Survey Analysis: Distribution by Location of Respondents
Figure 13.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 13.4 Survey Analysis: Distribution by Focus Area of the Company
Figure 13.5 Survey Analysis: Distribution by Type of Lead Products(s)
Figure 13.6 Survey Analysis: Distribution by Purpose of Lead Product(s)
Figure 13.7 Survey Analysis: Distribution by Commercial Availability of Lead Product(s)
Figure 13.8 Survey Analysis: Distribution by Likely Market Size of Prenatal Testing
Figure 13.9 Survey Analysis: Distribution by Likely Market Size of Newborn Screening

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report